MAP2 and Alzheimer disease: Despite the presence of severe NFT Braak and amyloid stages among the AD cases, the levels of SH3 and multiple ankyrin repeat domains protein 2 and MAP2 were not reduced in AD compared to controls (Fig. 3A–D).